OBJECTIVES: Statins and fibrates are hypolipidemic drugs which decrease cardiac events in individuals without raised levels of cholesterol. These drugs inhibit platelet function, but the mechanisms by which this pleiotropic effect is exerted are not known. METHODS AND RESULTS: We used a range of approaches to show statins inhibit human platelet activation in vitro while engaging PPARalpha and PPARgamma. The effects of simvastatin were prevented by the PPARgamma antagonist GW9662 or the PPARalpha antagonist GW6471. In a small-scale human study fluvastatin activated PPARalpha and PPARgamma in platelets and reduced aggregation in response to arachidonic acid ex vivo. The effects of fenofibrate were prevented by PPARalpha antagonism with GW6471. Fenofibrate increased bleeding time in wild-type, but not in PPARalpha-/- mice. The inhibitory effect of fenofibrate, but not simvastatin, on aggregation was prevented by deletion of PPARalpha in murine platelets. PKCalpha, which influences platelet activation, associated and immune-precipitated with PPARgamma in platelets stimulated with statins and with PPARalpha in platelets stimulated with fenofibrate. CONCLUSIONS: This study is the first to provide a unifying explanation of how fibrates and statins reduce thrombotic and cardiovascular risk. Our findings that PPARs associate with PKCalpha in platelets also provide a mechanism by which these effects are mediated.
OBJECTIVES: Statins and fibrates are hypolipidemic drugs which decrease cardiac events in individuals without raised levels of cholesterol. These drugs inhibit platelet function, but the mechanisms by which this pleiotropic effect is exerted are not known. METHODS AND RESULTS: We used a range of approaches to show statins inhibit human platelet activation in vitro while engaging PPARalpha and PPARgamma. The effects of simvastatin were prevented by the PPARgamma antagonist GW9662 or the PPARalpha antagonist GW6471. In a small-scale human study fluvastatin activated PPARalpha and PPARgamma in platelets and reduced aggregation in response to arachidonic acid ex vivo. The effects of fenofibrate were prevented by PPARalpha antagonism with GW6471. Fenofibrate increased bleeding time in wild-type, but not in PPARalpha-/- mice. The inhibitory effect of fenofibrate, but not simvastatin, on aggregation was prevented by deletion of PPARalpha in murine platelets. PKCalpha, which influences platelet activation, associated and immune-precipitated with PPARgamma in platelets stimulated with statins and with PPARalpha in platelets stimulated with fenofibrate. CONCLUSIONS: This study is the first to provide a unifying explanation of how fibrates and statins reduce thrombotic and cardiovascular risk. Our findings that PPARs associate with PKCalpha in platelets also provide a mechanism by which these effects are mediated.
Authors: M Grabacka; P Waligorski; A Zapata; D A Blake; D Wyczechowska; A Wilk; M Rutkowska; H Vashistha; R Ayyala; T Ponnusamy; V T John; F Culicchia; A Wisniewska-Becker; K Reiss Journal: J Physiol Pharmacol Date: 2015-04 Impact factor: 3.011
Authors: Louise S Harrington; Laura Moreno; Anna Reed; Stephen J Wort; Béatrice Desvergne; Christopher Garland; Lan Zhao; Jane A Mitchell Journal: PLoS One Date: 2010-03-04 Impact factor: 3.752
Authors: Charles E Leonard; Colleen M Brensinger; Warren B Bilker; Stephen E Kimmel; Xu Han; Young Hee Nam; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy Journal: Int J Cardiol Date: 2016-11-12 Impact factor: 4.164
Authors: Guillermo A Silva-Martínez; Dalia Rodríguez-Ríos; Yolanda Alvarado-Caudillo; Alejandro Vaquero; Manel Esteller; F Javier Carmona; Sebastian Moran; Finn C Nielsen; Marie Wickström-Lindholm; Katarzyna Wrobel; Kazimierz Wrobel; Gloria Barbosa-Sabanero; Silvio Zaina; Gertrud Lund Journal: Epigenetics Date: 2016-04-18 Impact factor: 4.528
Authors: Bedrich Mosinger; Kevin M Redding; M Rockwell Parker; Valeriya Yevshayeva; Karen K Yee; Katerina Dyomina; Yan Li; Robert F Margolskee Journal: Proc Natl Acad Sci U S A Date: 2013-07-01 Impact factor: 11.205